139.390 -

-0.330 (-0.24%)
Range 138.935 - 140.510   (1.13%)
Open 139.750
Previous Close 139.720
Bid Price 139.380
Bid Volume 111
Ask Price 139.450
Ask Volume 699
Volume 2,151,565
Value 232,712,549
Remark -
Delayed prices. Updated at 30 Jan 2026 00:50.
Data powered by
View All Events

About Gilead Sciences

Gilead Sciences, Inc. (Gilead) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Gilead�s primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases, such as hepatitis B and C and cardiovascular/metabolic and respiratory conditions. The Company has operations in North America, Europe and Asia Pacific. The Company�s products include Atripla, Truvada, Viread, Complera/Eviplera, Emtriva, Hepsera, Letairis, Ranexa, Lexiscan/Rapiscan, AmBisome, Vistide, Macugen, Cayston and Tamiflu. In January 2012, the Company acquired Pharmasset, Inc. On February 8, 2013, its subsidiary, acquired YM BioSciences Inc.

There are 30 followers

Followers
0
Followers
4
Followers
7
Followers
0
Followers
0
Followers
0
Followers
0
Followers
0
A pokemon who eat and sleep all day !
Followers
180
Followers
1
Followers
5
Followers
3
Followers
0
Followers
1
Followers
0
Followers
0
Followers
1
Followers
0
Followers
2
Followers
0
Followers
0
Followers
1
Investment research
Followers
0
trader
Followers
10
Followers
6
Followers
0
Followers
0
Followers
0
Followers
0
Followers
0